Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.
about
Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndromeUpdate on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.Effect of clobazam as add-on antiepileptic drug in patients with epilepsy.Pharmacogenomics--how close/far are we to practising individualized medicine for children?Genetic polymorphism of drug refractory epilepsyPharmacotherapy for Dravet Syndrome.Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studiesA Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.Methodologies used to identify and characterize interactions among antiepileptic drugs.Clobazam: a newly approved but well-established drug for the treatment of intractable epilepsy syndromes.New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel.Pharmacogenomics in epilepsy.Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.Drug-metabolism mechanism: Knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions.An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics.Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico.Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.PharmGKB summary: clobazam pathway, pharmacokinetics.Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy
P2860
Q26823805-DA000A41-74F0-472F-9223-5F16DF9EFB98Q33664128-AB949780-C125-460E-B9B5-9C7E5D40E064Q34437102-611D9AF9-DB3A-45A2-BA30-E4AAC5D85A07Q35135951-774066E9-A4CB-481F-9D13-352F8A33CA72Q35351642-6CC0C8CB-3078-492C-B782-BACB73B8B3DAQ35953476-A8C390D2-9502-4E92-8B90-5B0FFFE6C03CQ36537180-75367C59-5FEA-445F-90AE-B322200D48BCQ37653402-12BB091A-424D-4481-97D2-130788197344Q38018676-496CE3BD-5D7D-497A-9922-7D9BD1F4252DQ38056697-0874CC77-EBA6-409D-A8FC-8BDBAEC5FE01Q38851234-265F9381-9015-4888-BC4A-F31FA39AC10CQ39084353-8555AB65-4213-4F97-9B6C-04350BE184F0Q39416423-3CE733B3-EF94-4A97-BCFC-A7D362DA0EE2Q40680312-DD1D6402-5E20-4A72-BA47-D277EB7C431DQ40772054-C5DAFB90-569B-4CEE-96E5-0C4536EF4594Q42324494-6AB41F0A-A706-4749-91C9-9413B5F985F3Q42985589-E1307829-5B66-4172-9738-1B2F08C5B85AQ52667006-C169D012-75C7-4D15-8818-FDD436B11169Q57770173-90E8B867-716D-4A50-93D5-9CBCF7051732
P2860
Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.
@en
Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.
@nl
type
label
Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.
@en
Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.
@nl
prefLabel
Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.
@en
Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.
@nl
P2093
P2860
P356
P1433
P1476
Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.
@en
P2093
Chisato Takaishi
Kazuko Nakagawa
Masaharu Hori
Rie Nagata
Takateru Ishitsu
Takayuki Seo
Tsukasa Murata
P2860
P304
P356
10.2217/14622416.9.5.527
P577
2008-05-01T00:00:00Z